Search Results

You are looking at 171 - 180 of 452 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin

therapy referred to starting chemotherapy and RT within 14 days of each other, with the remainder designated as sequential. 25 , 26 Patients with an interval of >6 months from surgery to adjuvant therapy, or between adjuvant RT and chemotherapy, were

Full access

Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults

involvement (69%), and without perineural invasion (96%) or lymphovascular invasion (94%). Most tumors were primarily resected (81%), and most adjuvant therapy was used in higher T-class cases (see supplemental eTable 2) . Of patients undergoing excision, 15

Full access

Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang

only a small portion of patients with stage II CRC, but is unnecessary in up to 70% of patients who might be cured by surgery alone. 5 , 6 According to a recent Cochrane systematic review, adjuvant therapy improves overall survival (OS) in <10% of

Full access

Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng

adjuvant therapy has been shown to negatively impact outcomes in stage III colon cancer 5 and stage I–III breast cancer. 6 Although a few studies have found a paradoxical relationship of shorter treatment initiation intervals correlating with

Full access

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

intuitively would delay the initiation of adjuvant therapy. Patients with underweight BMI may be sarcopenic, which leads to increased postoperative complications. 26 Being underweight at diagnosis has been shown as an independent, adverse prognostic factor in

Full access

Eric Jonasch

not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave

Full access

Amanda N. Fader

extent of adjuvant therapy, and managing locoregional recurrence. In fact, laparoscopy has become the gold standard treatment of many gynecologic conditions, “both benign and malignant,” reported Dr. Fader. Many studies have shown improved outcomes with

Full access

Stephen B. Edge and David G. Sheldon

cancer patients receiving no adjuvant therapy . J Clin Oncol 2001 ; 19 : 1468 – 1475 . 37 Gray RJ Cox CE Reintgen DS . Importance of missed axillary micrometastases in breast cancer patients . Breast J 2001 ; 7 : 303 – 307 . 38

Full access

Hiram S. Cody III and Kimberly J. Van Zee

. AJCC Cancer Staging Manual ( Sixth Edition ). New York : Springer-Verlag , 2002 . 58 Ravdin PM Siminoff IA Harvey JA . Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy . J Clin Oncol

Full access

Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty

Edited by Kerrin G. Robinson

. Laparoscopic adrenalectomy for malignant disease . Lancet Oncol 2004 ; 5 : 718 – 726 . 40 Dickstein G Shechner C Arad E . Is there a role for low doses of mitotane (o,p’-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol